Skip to main content
ROIV
NASDAQ Life Sciences

Roivant Reports Widened Losses Amidst Strong Liquidity, Positive Clinical & Legal Updates, and New Share Repurchase Program

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$23
Mkt Cap
$14.703B
52W Low
$8.73
52W High
$23.91
52W Position info
163% above low
Off High info
3.8% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ROIV has more than doubled off its 52-week low of $8.73.

Summary

Roivant Sciences reported a widened net loss for the nine months ended December 31, 2025, but highlighted a strong cash position, positive clinical and legal developments, and new share repurchase authorization.


Key Events · Earnings and Guidance · ROIV

  • Widened Net Loss and Accumulated Deficit

    The company reported a net loss of $(753.7) million for the nine months ended December 31, 2025, significantly wider than the $(104.4) million loss in the prior year, and shifted to an accumulated deficit of $(695.0) million.

  • Strong Liquidity Position

    Roivant maintains a substantial cash, cash equivalents, and marketable securities balance of approximately $4.5 billion as of December 31, 2025, providing a long operational runway.

  • Positive Clinical and Legal Updates

    The filing highlights positive Phase 2 results for brepocitinib in cutaneous sarcoidosis and a favorable summary judgment in the U.S. Moderna patent litigation, reinforcing pipeline and intellectual property strength.

  • Strategic Capital Management

    Immunovant, a subsidiary, completed a $550 million financing, increasing Roivant's ownership to 56%. Additionally, the board authorized a new $500 million share repurchase program, following the completion of a previous $1.5 billion program.


Analysis · ROIV · Life Sciences

This quarterly report provides a comprehensive financial update, revealing a significant widening of net losses for the nine months ended December 31, 2025, and a shift to an accumulated deficit. Despite this, the company maintains a robust cash position of approximately $4.5 billion, which management believes provides a long operational runway. The filing also reiterates recent positive clinical data for brepocitinib and a favorable outcome in the ongoing Moderna patent litigation, both of which are key catalysts. Furthermore, Roivant's active capital management, including a successful $550 million financing for its subsidiary Immunovant and the authorization of a new $500 million share repurchase program, signals confidence. Investors should weigh the increased burn rate against the company's strong liquidity and pipeline progress, especially as the stock trades near its 52-week high, reflecting market optimism around these developments.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ROIV was trading at $23.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.7B. The 52-week trading range was $8.73 to $23.91. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ROIV - Latest Insights

ROIV
Nov 09, 2026, 7:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.37
Real-time Price: $39.53 info
Change: -$1.84 (-4%) info
Market Cap: $28.642B info
ROIV
Nov 09, 2026, 7:17 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $41.00
Real-time Price: $39.53 info
Change: -$1.47 (-4%) info
Market Cap: $28.642B info
ROIV
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $40.39
Real-time Price: $39.53 info
Change: -$0.860 (-2%) info
Market Cap: $28.642B info
ROIV
Oct 21, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.20
Real-time Price: $39.53 info
Change: +$3.33 (+9%) info
Market Cap: $28.642B info
ROIV
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $36.60
Real-time Price: $39.53 info
Change: +$2.93 (+8%) info
Market Cap: $28.642B info